Odetiglucan is under clinical development by Hibercell and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Odetiglucan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Odetiglucan overview

Odetiglucan (BTH-1677) is under development for the treatment of cutaneous melanoma, advanced indolent non-hodgkin's lymphoma, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), non-small cell lung cancer,  and patients with stage IV KRAS-mutated colorectal cancer, metastatic melanoma, metastatic breast cancer, metastatic triple negative breast cancer, pancreatic ductal adenocarcinoma, metastatic pancreatic adenocarcinoma and liver metastasis. The drug candidate is administered intravenously. It acts by targeting dectin-1, CR3, Fc gamma receptor and is being developed based on QuAD³ Platform. It is a soluble polysaccharide beta 1,3/1,6 glucan and is derived from the cell wall of the yeast Saccharomyces cerevisiae.

It was also under development for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, metastatic colorectal cancer and metastatic colorectal cancer (third-line therapy), chronic lymphocytic leukemia.

Hibercell overview

Hibercell is a biotechnology company that discovers and develops therapies for treatment of cancer. The company is investigating odetiglucan, an immune modulator candidate that enhances immune functions for the treatment of CRC-based liver Metastasis, pancreatic cancer and liver metastasis. It is also developing adaptive stress response modulator programs, HC-5404 for treatment of renal cell carcinoma, gastric cancer and others advanced solid tumors and HC-7366 to treat head and neck, colorectal and bladder cancer. Hibercell is headquartered in New York, the US.

For a complete picture of Odetiglucan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.